New hope for advanced colorectal cancer: EMB-01 trial launches

NCT ID NCT07314294

Recruiting now Disease control Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called EMB-01 in people with advanced colorectal cancer that has come back or spread. The goal is to see if different dosing schedules can shrink tumors and how safe the drug is. About 54 adults will take part, and they will be assigned to receive EMB-01 either once a week or once a week for 6 weeks then every two weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, China
The Sixth Affiliated Hospital of Sun Yat-Sen University
NOT_YET_RECRUITING

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.